Medication for itching caused by immunotherapy
Part of Skin clinical trials.
This trial tests if the drug Aprepitant can help relieve itching caused by immunotherapy treatments in people with solid tumors. It is for those whose itching has not responded to standard treatments or started after beginning immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor cancer like melanoma, kidney, or lung cancer.
- You are currently receiving immunotherapy drugs (like nivolumab or pembrolizumab).
- You have itching that is either new since starting immunotherapy or has not gotten better with usual treatments.
- You are able to care for yourself (ECOG score 0-2).
- You are willing to follow study rules and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
This study compares two oral medications—methotrexate and apremilast—to see which works better for relieving itching in people with psoriasis. If you have psoriasis and bothersome itching, you may be able to join.
This trial tests a special light treatment (photobiomodulation) to see if it can safely reduce itch. It compares the treated area to a similar untreated area on your body.
This trial tests a new medication, TH104, to see if it can reduce itching caused by primary biliary cholangitis (PBC). Itching is a common symptom of PBC, and this study aims to find a more effective treatment.
This trial tests a gel called TriCalm Hydrogel to see if it helps reduce itching caused by immunotherapy cancer treatment. If you have itching from your immunotherapy, this study might offer relief.
This study checks blood antibodies (BP180 and BP230) in people who develop long-lasting itching after starting immune therapy for cancer. It may help doctors understand why the itching happens and how it relates to autoimmune skin conditions.
Hear when a new Pruritus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.